Page 1 | Search Results | Diabetes | American Diabetes Association

1-20 of 171

Sort by

Sort Order Select

Journal Articles

Lysophosphotidylinositols (LysoPIs) are upregulated following human ß-cell loss and act to potentiate insulin release.

Diabetes db230205

Published: 20 October 2023

View article titled, Lysophosphotidylinositols (LysoPIs) are upregulated following human ß-cell loss and act to potentiate insulin release.

Meeting Abstracts

1804-PUB: Switching from Glucagon-Like Peptide-1 Receptor Agonists Therapy to Second Generation Basal Insulins—Comparative Effectiveness Analysis of Glargine 300 U/mL vs. Degludec 100 U/mL—The RESTORE-G Real-World Study

RICCARDO CANDIDO, ANTONIO NICOLUCCI, MONICA LAROSA, MARIA CHIARA ROSSI, RAFFAELE NAPOLI, RESTORE-G STUDY GROUP

Diabetes 2023;72(Supplement_1):1804-PUB

https://doi.org/10.2337/db23-1804-PUB

Published: 23 June 2023

View article titled, 1804-PUB: Switching from Glucagon-Like Peptide-1 Receptor Agonists Therapy to Second Generation Basal Insulins—Comparative Effectiveness Analysis of Glargine 300 U/mL vs. Degludec 100 U/mL—The RESTORE-G Real-World Study

Meeting Abstracts

63-LB: Real-Time Continuous Glucose Monitoring (rtCGM) Is Associated with Improved Clinical and Psychosocial Health in People with Type 2 Diabetes on Basal Insulin (T2D-BI)

MARGARET A. CRAWFORD, CHRISTIAN HICKS, TERESA ZHOU, AFSHAN KLEINHANZL, HARSIMRAN SINGH

Diabetes 2023;72(Supplement_1):63-LB

https://doi.org/10.2337/db23-63-LB

Published: 20 June 2023

View article titled, 63-LB: Real-Time Continuous Glucose Monitoring (rtCGM) Is Associated with Improved Clinical and Psychosocial Health in People with Type 2 Diabetes on Basal Insulin (T2D-BI)

Meeting Abstracts

132-LB: Real-World Effectiveness of My Dose Coach (MDC)-Assisted Basal Insulin (BI) Titration in People with Type 2 Diabetes (PWT2D) in Saudi Arabia and Kuwait

MOHAMMED AL-SOFIANI, MOHAMMED ALMEHTHEL, EBAA S. ALOZAIRI, JAMAA SADIK, LICHEN HAO, YASSER AKIL

Diabetes 2023;72(Supplement_1):132-LB

https://doi.org/10.2337/db23-132-LB

Published: 20 June 2023

View article titled, 132-LB: Real-World Effectiveness of My Dose Coach (MDC)-Assisted Basal Insulin (BI) Titration in People with Type 2 Diabetes (PWT2D) in Saudi Arabia and Kuwait

Meeting Abstracts

932-P: Impact of a Titration App for Basal Insulin on Glycaemic Outcomes in People with Type 2 Diabetes on an Oral-Basal Insulin Regimen—Results of an RCT

NORBERT HERMANNS, DOMINIC EHRMANN, TIMM ROOS, KATHARINA FINKE-GROENE, BERNHARD KULZER

Diabetes 2023;72(Supplement_1):932-P

https://doi.org/10.2337/db23-932-P

Published: 20 June 2023

View article titled, 932-P: Impact of a Titration App for Basal Insulin on Glycaemic Outcomes in People with Type 2 Diabetes on an Oral-Basal Insulin Regimen—Results of an RCT

Meeting Abstracts

816-P: Predictors of Adherence and Persistence to Basal Insulin Therapy in Adults with Type 2 Diabetes

VANITA R. ARODA, NICK F. NIELSEN, KAMAL K. MANGLA, YI WANG, TARLAN NAMVAR, JIGAR R. RAJPURA

Diabetes 2023;72(Supplement_1):816-P

https://doi.org/10.2337/db23-816-P

Published: 20 June 2023

View article titled, 816-P: Predictors of Adherence and Persistence to Basal Insulin Therapy in Adults with Type 2 Diabetes

Meeting Abstracts

806-P: Once Weekly (QW) Basal Insulin Fc (BIF) and Daily Degludec (DEG) Achieve Comparable Glycemic Control in Three Patient Populations Studied during Phase 2—Clinical Insights from CGM Assessments

CHRISTOF M. KAZDA, JULIANA M. BUE-VALLESKEY, QIANYI ZHANG, AXEL HAUPT, JUAN P. FRIAS, DOMINIK DAHL

Diabetes 2023;72(Supplement_1):806-P

https://doi.org/10.2337/db23-806-P

Published: 20 June 2023

View article titled, 806-P: Once Weekly (QW) Basal Insulin Fc (BIF) and Daily Degludec (DEG) Achieve Comparable Glycemic Control in Three Patient Populations Studied during Phase 2—Clinical Insights from CGM Assessments

Meeting Abstracts

772-P: Tirzepatide vs. Basal Insulins in People with T2D and Different Baseline Glycemic Patterns—Post Hoc Analyses of the SURPASS-3 and -4 Trials

FRANCESCO GIORGINO, DENISE R. FRANCO, CLAUDIA NICOLAY, ANDREA HEMMINGWAY, ÁNGEL RODRÍGUEZ, RUSSELL WIESE

Diabetes 2023;72(Supplement_1):772-P

https://doi.org/10.2337/db23-772-P

Published: 20 June 2023

View article titled, 772-P: Tirzepatide vs. Basal Insulins in People with T2D and Different Baseline Glycemic Patterns—Post Hoc Analyses of the SURPASS-3 and -4 Trials

Meeting Abstracts

134-LB: Real-World Impact of Intermittently Scanned Continuous Glucose Monitoring on Hemoglobin A1c in People with Type 2 Diabetes in Canada That Use Basal Insulin—A Prospective Chart Review

ALEXANDER ABITBOL, AKSHAY B. JAIN, MICHAEL TSOUKAS, JOHN SIGALAS, BRANDON P. GALM, JOOHO LEE, KAMRAN S. QURESHY, JR., CAITLYN COLLINS, VINCENT C. WOO

Diabetes 2023;72(Supplement_1):134-LB

https://doi.org/10.2337/db23-134-LB

Published: 20 June 2023

View article titled, 134-LB: Real-World Impact of Intermittently Scanned Continuous Glucose Monitoring on Hemoglobin A1c in People with Type 2 Diabetes in Canada That Use Basal Insulin—A Prospective Chart Review

Meeting Abstracts

779-P: Intensification of Glucagon-Like Peptide-1 Receptor Agonists Therapy with First and Second Generation Basal Insulins—The RESTORE-G Real-World Study

RAFFAELE NAPOLI, MONICA LAROSA, ANTONIO NICOLUCCI, MARIA CHIARA ROSSI, RICCARDO CANDIDO, RESTORE-G STUDY GROUP

Diabetes 2023;72(Supplement_1):779-P

https://doi.org/10.2337/db23-779-P

Published: 20 June 2023

View article titled, 779-P: Intensification of Glucagon-Like Peptide-1 Receptor Agonists Therapy with First and Second Generation Basal Insulins—The RESTORE-G Real-World Study

Meeting Abstracts

753-P: Tirzepatide Improves HRQoL Compared with Insulin Lispro in Poorly Controlled Basal Insulin–Treated Adults with Long-Standing T2D (SURPASS-6)

KRISTINA BOYE, HELENE SAPIN, JIAT LING POON, LAURA FERNANDEZ LANDO, RUTH HUH, MIANBO WANG, HIREN PATEL

Diabetes 2023;72(Supplement_1):753-P

https://doi.org/10.2337/db23-753-P

Published: 20 June 2023

View article titled, 753-P: Tirzepatide Improves HRQoL Compared with Insulin Lispro in Poorly Controlled Basal Insulin–Treated Adults with Long-Standing T2D (SURPASS-6)

Meeting Abstracts

74-LB: Transition from Basal Bolus to Once-Weekly Subcutaneous Semaglutide and Basal Insulin in Patients with Type 2 Diabetes Mellitus (TRANSITION-T2D)—A Prospective Randomized Controlled Trial

PALOMA RODRIGUEZ, NIKKI BRESLAW, JAMES F. BENA, HUIJUN XIAO, KIMBERLY JENKINS, DIANA ISAACS, KEREN ZHOU, MARCIO L. GRIEBELER, BARTO BURGUERA, KEVIN M. PANTALONE

Diabetes 2023;72(Supplement_1):74-LB

https://doi.org/10.2337/db23-74-LB

Published: 20 June 2023

View article titled, 74-LB: Transition from Basal Bolus to Once-Weekly Subcutaneous Semaglutide and Basal Insulin in Patients with Type 2 Diabetes Mellitus (TRANSITION-T2D)—A Prospective Randomized Controlled Trial

Meeting Abstracts

558-P: Online Medical Education Advances Physicians’ Knowledge and Competence for the Use of Basal Insulin

JOACHIM TRIER, HARPREET S. BAJAJ, ATHENA PHILIS-TSIMIKAS

Diabetes 2023;72(Supplement_1):558-P

https://doi.org/10.2337/db23-558-P

Published: 20 June 2023

View article titled, 558-P: Online Medical Education Advances Physicians’ Knowledge and Competence for the Use of Basal Insulin

Meeting Abstracts

1001-P: Adherence and Persistence to Basal Insulin Therapy Is Associated with Decreased Health Care Utilization in Adults with Type 2 Diabetes

NICK F. NIELSEN, VANITA R. ARODA, KAMAL K. MANGLA, VICTORIA DIVINO, TARLAN NAMVAR, JIGAR R. RAJPURA

Diabetes 2023;72(Supplement_1):1001-P

https://doi.org/10.2337/db23-1001-P

Published: 20 June 2023

View article titled, 1001-P: Adherence and Persistence to Basal Insulin Therapy Is Associated with Decreased Health Care Utilization in Adults with Type 2 Diabetes

Meeting Abstracts

666-P: How Satisfied Are People with Type 2 Diabetes with a Basal Insulin Titration App? Findings from the Intervention Group of a Randomized Controlled Trial

DOMINIC EHRMANN, NORBERT HERMANNS, TIMM ROOS, KATHARINA FINKE-GROENE, BERNHARD KULZER

Diabetes 2023;72(Supplement_1):666-P

https://doi.org/10.2337/db23-666-P

Published: 20 June 2023

View article titled, 666-P: How Satisfied Are People with Type 2 Diabetes with a Basal Insulin Titration App? Findings from the Intervention Group of a Randomized Controlled Trial

Meeting Abstracts

794-P: Effectiveness and Safety of iGlarLixi in People with Type 2 Diabetes (Pw2D), Not at Target on Basal Insulin (BI) and Oral Antidiabetic Therapy (BOT)—Results from the Observational, Prospective Study CHANCE

TOBIAS WIESNER, MARTIN PFOHL, KATRIN PEGELOW, JULIA MÜLLER, JOCHEN SEUFERT

Diabetes 2023;72(Supplement_1):794-P

https://doi.org/10.2337/db23-794-P

Published: 20 June 2023

View article titled, 794-P: Effectiveness and Safety of iGlarLixi in People with Type 2 Diabetes (Pw2D), Not at Target on Basal Insulin (BI) and Oral Antidiabetic Therapy (BOT)—Results from the Observational, Prospective Study CHANCE

Meeting Abstracts

156-LB: Nursing Burden Administering/Monitoring Complex Insulin Regimens vs. Basal Insulin/GLP-1 RA Fixed-Ratio Combinations (FRCs) for People with Type 2 Diabetes (PWT2D) in Long-Term Care (LTC)

HARLEY E. DAVIDSON, ASHLEY NELSON, LISA F. HAN, MELISSA LAMANTIA, KERRY DESAI, XUAN LI, TERRY A. DEX, JACQUELINE F. VANCE, KEVIN OVERBECK

Diabetes 2023;72(Supplement_1):156-LB

https://doi.org/10.2337/db23-156-LB

Published: 20 June 2023

View article titled, 156-LB: Nursing Burden Administering/Monitoring Complex Insulin Regimens vs. Basal Insulin/GLP-1 RA Fixed-Ratio Combinations (FRCs) for People with Type 2 Diabetes (PWT2D) in Long-Term Care (LTC)

Meeting Abstracts

811-P: Initiation of Once-Weekly (QW) Basal Insulin Fc (BIF) in Three Patient Populations in Phase 2 Studies Using a One-Time Loading Dose (LD) Minimizes Transient Hyperglycemia and Is Not Associated with Excess Hypoglycemia Risk vs. Degludec

JULIANA M. BUE-VALLESKEY, CHRISTOF M. KAZDA, QIANYI ZHANG, AXEL HAUPT, DOMINIK DAHL, JUAN P. FRIAS

Diabetes 2023;72(Supplement_1):811-P

https://doi.org/10.2337/db23-811-P

Published: 20 June 2023

View article titled, 811-P: Initiation of Once-Weekly (QW) Basal Insulin Fc (BIF) in Three Patient Populations in Phase 2 Studies Using a One-Time Loading Dose (LD) Minimizes Transient Hyperglycemia and Is Not Associated with Excess Hypoglycemia Risk vs. Degludec

Meeting Abstracts

803-P: Superior Glycemic Control with Once-Weekly Insulin Icodec with a Dosing Guide App vs. Once-Daily (OD) Basal Insulin Analogs in Insulin-Naïve T2D—ONWARDS 5

HARPREET S. BAJAJ, JENS ABERLE, MELANIE J. DAVIES, ANDERS M. DONATSKY, MARIE FREDERIKSEN, DILEK GOGAS YAVUZ, AMOOLYA GOWDA, ILDIKO LINGVAY, BRUCE W. BODE

Diabetes 2023;72(Supplement_1):803-P

https://doi.org/10.2337/db23-803-P

Published: 20 June 2023

View article titled, 803-P: Superior Glycemic Control with Once-Weekly Insulin Icodec with a Dosing Guide App vs. Once-Daily (OD) Basal Insulin Analogs in Insulin-Naïve T2D—ONWARDS 5

Meeting Abstracts

818-P: Glycemic Control in Naïve Users of Second-Generation Basal Insulins with T2D and CKD—A Nationwide Register-Based Cohort Study

VANJA KOSJERINA, BENDIX CARSTENSEN, HANAN AMADID, DORTE VISTISEN

Diabetes 2023;72(Supplement_1):818-P

https://doi.org/10.2337/db23-818-P

Published: 20 June 2023

View article titled, 818-P: Glycemic Control in Naïve Users of Second-Generation Basal Insulins with T2D and CKD—A Nationwide Register-Based Cohort Study

NARROW

Lysophosphotidylinositols (LysoPIs) are upregulated following human ß-cell loss and act to potentiate insulin release.

1804-PUB: Switching from Glucagon-Like Peptide-1 Receptor Agonists Therapy to Second Generation Basal Insulins—Comparative Effectiveness Analysis of Glargine 300 U/mL vs. Degludec 100 U/mL—The RESTORE-G Real-World Study

63-LB: Real-Time Continuous Glucose Monitoring (rtCGM) Is Associated with Improved Clinical and Psychosocial Health in People with Type 2 Diabetes on Basal Insulin (T2D-BI)

132-LB: Real-World Effectiveness of My Dose Coach (MDC)-Assisted Basal Insulin (BI) Titration in People with Type 2 Diabetes (PWT2D) in Saudi Arabia and Kuwait

932-P: Impact of a Titration App for Basal Insulin on Glycaemic Outcomes in People with Type 2 Diabetes on an Oral-Basal Insulin Regimen—Results of an RCT

816-P: Predictors of Adherence and Persistence to Basal Insulin Therapy in Adults with Type 2 Diabetes

806-P: Once Weekly (QW) Basal Insulin Fc (BIF) and Daily Degludec (DEG) Achieve Comparable Glycemic Control in Three Patient Populations Studied during Phase 2—Clinical Insights from CGM Assessments

772-P: Tirzepatide vs. Basal Insulins in People with T2D and Different Baseline Glycemic Patterns—Post Hoc Analyses of the SURPASS-3 and -4 Trials

134-LB: Real-World Impact of Intermittently Scanned Continuous Glucose Monitoring on Hemoglobin A1c in People with Type 2 Diabetes in Canada That Use Basal Insulin—A Prospective Chart Review

779-P: Intensification of Glucagon-Like Peptide-1 Receptor Agonists Therapy with First and Second Generation Basal Insulins—The RESTORE-G Real-World Study

753-P: Tirzepatide Improves HRQoL Compared with Insulin Lispro in Poorly Controlled Basal Insulin–Treated Adults with Long-Standing T2D (SURPASS-6)

74-LB: Transition from Basal Bolus to Once-Weekly Subcutaneous Semaglutide and Basal Insulin in Patients with Type 2 Diabetes Mellitus (TRANSITION-T2D)—A Prospective Randomized Controlled Trial

558-P: Online Medical Education Advances Physicians’ Knowledge and Competence for the Use of Basal Insulin

1001-P: Adherence and Persistence to Basal Insulin Therapy Is Associated with Decreased Health Care Utilization in Adults with Type 2 Diabetes

666-P: How Satisfied Are People with Type 2 Diabetes with a Basal Insulin Titration App? Findings from the Intervention Group of a Randomized Controlled Trial

794-P: Effectiveness and Safety of iGlarLixi in People with Type 2 Diabetes (Pw2D), Not at Target on Basal Insulin (BI) and Oral Antidiabetic Therapy (BOT)—Results from the Observational, Prospective Study CHANCE

156-LB: Nursing Burden Administering/Monitoring Complex Insulin Regimens vs. Basal Insulin/GLP-1 RA Fixed-Ratio Combinations (FRCs) for People with Type 2 Diabetes (PWT2D) in Long-Term Care (LTC)

811-P: Initiation of Once-Weekly (QW) Basal Insulin Fc (BIF) in Three Patient Populations in Phase 2 Studies Using a One-Time Loading Dose (LD) Minimizes Transient Hyperglycemia and Is Not Associated with Excess Hypoglycemia Risk vs. Degludec

803-P: Superior Glycemic Control with Once-Weekly Insulin Icodec with a Dosing Guide App vs. Once-Daily (OD) Basal Insulin Analogs in Insulin-Naïve T2D—ONWARDS 5

818-P: Glycemic Control in Naïve Users of Second-Generation Basal Insulins with T2D and CKD—A Nationwide Register-Based Cohort Study

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

This Feature Is Available To Subscribers Only